Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Marijuana Reclassification and APRN/PA Prescribing

Client Alert
May 7, 2024

Overview

Marijuana is expected to be reclassified by the Drug Enforcement Administration (DEA) from a Schedule I controlled substance to a Schedule III controlled substance as a result of efforts by the Biden administration.

Schedule I controlled substances are defined under the Controlled Substances Act as having a high potential for abuse, no currently accepted medical use in treatment in the U.S., and a lack of accepted safety for use of the drug under medical supervision. By contrast, Schedule III substances are defined as having a potential for abuse less than drugs in Schedules I and II, have a currently accepted medical use in treatment in the U.S., and abuse of the drug may lead to moderate or low physical dependence or high psychological dependence.[1]

Effect on APRN and PA Prescribing in Ohio

Providers, including advanced practice registered nurses (APRNs) and physician assistants (PAs) are not permitted to prescribe Schedule I controlled substances. Therefore, neither APRNs nor PAs in Ohio are permitted to prescribe marijuana to patients while still classified as a Schedule I controlled substance.

However, both APRNs and PAs are permitted to prescribe Schedule III controlled substances, so long as the medication is within the provider’s scope of practice. For APRNs, this means that the prescription is used to treat conditions consistent with their education, clinical experience, and national certification, and within the parameters of their standard care arrangement with a physician who is practicing in a specialty that is the same or similar to theirs.[2] The drug also cannot exceed the prescriptive authority of their collaborating physician.[3] Similarly, PAs with prescriptive authority are limited to prescribing drugs that are a part of their supervising physician’s normal course of practice and expertise and do not exceed their supervising physician’s prescriptive authority.[4] The prescription also should be consistent with the terms of their supervision agreement.

Analysis

While the reclassification of marijuana from Schedule I to III should allow for APRNs and PAs to prescribe marijuana, Ohio Revised Code Chapter 3796 may still stand in the way.

Specifically, the rule currently states that when a patient or their caregiver is seeking to use medical marijuana, “the physician who holds a certificate to recommend issued by the state medical board and is treating the patient or the physician's delegate shall submit the application on the patient's or caregiver's behalf…”[5]

“Physician” under Chapter 3796 is defined as, “an individual authorized under Chapter 4731 of the Revised Code to practice medicine and surgery or osteopathic medicine and surgery,” thus explicitly excluding APRNs and PAs.

Therefore, upon reclassification of marijuana, the question will be whether Ohio law also changes, doing away with the “certificate to recommend,” since providers will now be able to directly prescribe marijuana for their patients. Currently, the certificate to recommend allows patients with qualifying medical conditions to legally purchase and use marijuana.

If you have any questions regarding the pending reclassification of marijuana or general questions regarding APRNs or PAs, please don’t hesitate to contact BMD Health Law Group Member Jeana Singleton at jmsingleton@bmdllc.com or 330-253-2001, or BMD Attorney Rachel Stermer at rcstermer@bmdllc.com or 330-253-2019.  

[1] 21 U.S.C. § 812.

[2] ORC § 4723.431.

[3] ORC § 4723.481.

[4] ORC § 4730.20 and ORC § 4730.42.

[5] ORC § 3796.08.

Medical MarijuanaControlled SubstancesMarijuana LawHealth LawHealthcare Policy
Client Alert

Multi-340B Contract Pharmacy Locations on the Brink? The Third Circuit’s Ruling Gives a Hint.

February 17, 2023The 340B drug discount program requires pharmaceutical manufacturers to offer to sell their products at significant discounts to safety net providers called “covered entities.” In 1996, the Health Resources and Services Administration (HRSA) issued guidance authorizing covered entities to enter into a contract pharmacy arrangement with a single third-party contract pharmacy, to which the manufacturer would ship 340B medications but bill the covered entity. In 2010, HRSA issued revised guidance permitting covered entities to enter into an unlimited number of contract pharmacy arrangements.Client Alert

Five Opportunities for Operations and Compliance Excellence in 2023

February 17, 2023With the holidays behind us and the rest of the year ahead, now is the perfect time to get your operational/compliance house in order! Though your list might be a mile (or an inch) long, here are five places to start.Client Alert

The Pregnant Workers Fairness Act - What Employers Need to Know

February 17, 2023Effective June 27, 2023, the Pregnant Workers Fairness Act (PWFA) will require employers with at least 15 employees to provide reasonable accommodations for qualified employees with pregnancy-related restrictions unless doing so would impose an undue hardship on the employer.Client Alert

Valley National Bank/Trulieve Loan: A Big Step Out of the Shadows

January 18, 2023In a late December press release, Trulieve announced that it had secured a $71.5 million commercial bank loan. In addition to the amount of the loan, which may be the largest commercial bank loan to date to a cannabis company, the release prominently identified Valley Bank and featured both a quote from Valley’s Senior Vice President, John Myers, and a description of the Bank’s service platform and commitment to the cannabis industry.Client Alert

The End of Non-Competes? The Impact It Will Have on the Healthcare Industry

January 10, 2023On January 5, 2023, the Federal Trade Commission (“FTC”) announced a proposed rule that, if enacted, will ban employers from entering into non-compete clauses with workers (the “Rule”), and the Rule would void existing non-compete agreements. In their Notice, the FTC stated that if the Rule were to go into effect, they estimate the overall earnings of employees in the United States could increase by $250 billion to $296 billion per year. The Rule would also require employers to rescind non-competes that they had already entered into with their workers. For purposes of the Rule, the FTC has defined “worker” to also include any employees, interns, volunteers, and contractors.”
Older posts
Newer posts